- Home
- SXTP vs ENVB Comparison
SXTP vs ENVB Comparison
Compare SXTP & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | ENVB |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTP | ENVB |
|---|---|---|
| Price | $1.99 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $17.60 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 155.3K | 60.1K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,364,945.00 | N/A |
| Revenue This Year | $146.28 | N/A |
| Revenue Next Year | $24.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 202.10 | N/A |
| 52 Week Low | $1.36 | $3.50 |
| 52 Week High | $24.00 | $63.00 |
Technical Indicators
Market Signals| Indicator | SXTP | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 82.44 | 45.32 |
| Support Level | $0.34 | $3.67 |
| Resistance Level | $2.38 | $4.24 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | 0.17 | 0.05 |
| Stochastic Oscillator | 79.43 | 70.89 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.